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Introduction
It is well known that various interferons (IFNs) possess many biological activities including antiviral, antiproliferative and immunomodulating activities in man and animals.1) Natural human IFN-gamma, which is called "immune interferon," has been expected to have many potent immunomodulating activities, but the limited supply of highly purified IFN has prevented extensive study of this interesting lymphokine. A large amount of highly purified human IFN-gamma has recently become available by gene cloning into a strain of Escherichia coli.2) Recombinant human IFN-gamma (Met-Gin form) used in our study is a natural type having the same amino acid sequence as that of natural human IFN-gamma elucidated by Rinderknecht et al., 3) except for the N-terminal methionine residue. In our previous studies,4) we found that IFN-gamma (Met-Gin form) augmented human natural killer, antibodydependent cell-mediated cytotoxic (ADCC) and antibody-dependent monocyte-mediated cytotoxic (ADMC) activities like other IFNs, and that the augmentation of ADMC activity against anti-chicken red blood cell (CRBC) immunoglobulin G (IgG)-coated CRBC by IFNgamma (Met-Gin form) was more potent than that by natural human IFN-alpha and -beta when compared on the basis of antiviral activity. Since it is well known that, in the ADCC reaction, the effector cells are Fc receptor(FcR)-bearing cells and an increase of effector cell/target cell ratio enhances ADCC activity, it is supposed that the greater increase in the number of monocytes bearing FcR induced by IFN-gamma (Met-Gln form) as compared with natural human IFN-alpha and -beta might result in more effective augmentation of the ADMC activity. We, therefore, tried to confirm this hypothesis by measurement of the number of FcR-bearing monocytes after IFN treatment using flow cytometry and fluorescein isothiocyanate-labelled (FITC-) anti-CRBC IgG in this study. In addition to the analysis of FcR on human monocytes, we further studied the effects of these IFNs on the expression of FcRs on human lymphocytes and on the antibody-dependent lymphocyte-mediated cytotoxic (ADLC) activity against anti-CRBC IgG-coated CRBC.
Since there are many studies demonstrating the augmenting ability of IFN-gamma on the expression of Ia-like antigen on various cells, including monocytes and macrophages,5) we were very interested to examine whether IFN-gamma (Met-Gln form) enhances the expression of the antigen on monocytes and lymphocytes. Therefore, we compared the effects of IFN-gamma (Met-Gln form) on the expression with those of natural human IFN-alpha and -beta. In this formula, MR cpm was determined as cpm in the supernatant obtained after the lysis of 51Cr-labelled CRBCs with distilled water. SR cpm was determined as cpm released from 51Cr-labelled CRBCs incubated with RPMI 1640 medium containing 10% FCS alone in the absence of lymphocytes. Table I shows the effects of recombinant human IFN-gamma (Met-Gln form) and natural human IFN-alpha and -beta on the numbers of monocytes treated with FITC-anti-CRBC IgG in the six regions obtained by flow cytometry. As seen in Table I , IFN-gamma (Met-Gln form) greatly decreased the number of monocytes in region I but increased those in region II, III and IV. Further, another experiment revealed that this increasing effect was dose-dependent (Fig. 1) . However, the two natural IFNs did not show any apparent effect on the numbers in the six regions (Table I) .
Results

Analysis of FcR on Monocytes
The change of the percentage of monocytes bearing FcR binding to anti-CRBC IgG after treatment with each IFN or control solution is shown in Fig. 2A . Even on overnight incubation of fresh monocytes in control solution, the percentage was markedly decreased to 25% of the fresh control value. IFN-gamma (Met-Gln form) greatly increased the percentage when compared with the overnight control value ( Fig. 2A) and this increase was dosedependent (Fig. 3) . On the other hand, the natural IFNs showed no effect at 1000 unit/ml ( Fig.  2A) .
Analysis of FcR on Lymphocytes
The effects of the three IFNs on the number of lymphocytes treated with FITC-anti-CRBC IgG in the six regions obtained by flow cytometry are shown in Table II Each value represents the mean + S.E. of three donors. The IFN concentration used in the treatment of monocytes was 1000 unit/mi. Significant difference from overnight control, a) p <0.05; b) p < 0.02; c) p < 0.01 . A, fresh control; B, overnight control; C, 10 unit/ml; D, 100 unit/ml; E, 1000 unit/ml. These data were obtained from one donor. Similar results were also obtained from two other donors (data not shown), but we did not calculate mean values because there were some individual differences between the patterns of the three histograms. control. Figure 4A shows the effects of the three IFNs on the percentage of lymphocytes bearing FcR binding to anti-CRBC IgG in the lymphocyte preparation.
The percentage was unchanged by the treatment with each IFN or control solution in comparison with that of fresh lymphocytes.
Effects of IFNs on ADLC Activity Figure 5 shows the effects of the three IFNs on ADLC activity. The ADLC activity was not augmented even by treatment with 1000 unit/ml IFNs. Each value represents the mean + S.E. of three donors. The IFN concentration used in the treatment of lymphocytes was 1000 unit/mi. 
Analysis of Ia-like Antigen on Monocytes
The change of the numbers of monocytes binding to FITC-OKIal in the six regions after treatment with each IFN or control solution is shown in Table III . IFN-gamma (Met-Gin form) greatly decreased the number in region III, IV and V and increased that in region VI, but the natural IFNs caused no significant Change as compared with the overnight control value.
The effects of the three IFNs on the percentage of Ia-positive monocytes in the monocyte preparation are shown in Fig. 2B . Almost all of the monocytes were Ia-positive after overnight incubation in the control solution, and the three IFNs did not change the percentage. Each value represents the mean+ S.E. of three donors. The IFN concentration used in the treatment of monocytes was 1000 unit/ml. Significant difference from overnight control, a) p<0.05; b) p<0.01. Each value represents the mean + S.E. of three donors. The IFN concentration used in the treatment of lymphocytes was 1000 unit/ml. Fig. 4B .
Analysis of Ia-like Antigen on Lymphocytes
Discussion
We analyzed the FcR binding to anti-CRBC IgG on human monocytes using flow cytometry, demonstrating a dose-dependent increase of the number of FcRs on monocytes and monocytes bearing the FcR after treatment with recombinant human IFN-gamma (MetGln form) (Figs. 1 and 3) . The increasing effects on the number of monocytes bearing FcR induced by the IFN-gamma (Met-Gln form) were not observed with natural human IFNalpha and -beta (Figs. 2 and 3) . These results may directly explain why IFN-gamma (Met-Gin form) augmented ADMC activity against anti-CRBC IgG-coated CRBC more effectively than the natural IFNs when compared on the basis of antiviral activity, as shown in our previous report4) Namely, IFN-gamma (Met-Gln form) seems to augment ADMC activity by increasing the number of monocytes bearing FcRs binding to anti-CRBC IgG more effectively than the natural IFNs. In relation to these results, Guyre et al. demonstrated that recombinant human IFN-gamma (Cys-Tyr-Cys-Gln form) having Cys-Tyr-Cys-Gln at the N-terminal increased the number of FcR on human monocytes and cell line HL-60 and U-937 more markedly than recombinant human IFN-alpha and -beta.8) In the same report, they stated that their IFN-gamma enhanced ADCC activity without presenting any experimental data.8) Their results and ours indicate that human monocyte activation induced by recombinant human IFN-gamma may not require the N-terminal residue, Cys-Tyr-Cys, as described elsewhere.4) Since the present study showed no significant effect of the natural IFNs on the number of FcR-bearing monocytes, the weak or moderate augmentation of ADMC activity by the natural IFNs as shown in our previous report4) cannot be explained by an increase in the number of FcR-bearing monocytes. Therefore, other mechanisms of ADMCaugmentation by IFNs, for example, the enhancement of lytic ability of monocytes after binding to target cells or recruitment of monocytes participating in the ADMC reaction, cannot be excluded.
Although the expression of FcR on cell membrane of monocytes was induced by IFNgamma (Met-Gin form), such induction was not observed in lymphocytes (Fig. 2 and Table  II ). The finding is consistent with the lack of ADLC-augmentation by 1FN-gamma (Met-Gin form) (Fig. 4) . The natural IFNs also had no effect on the expression of FcR or ADLC activity in lymphocytes (Figs. 2 and 4 and Table II) . These results conflict with many previous studies demonstrating the IFN-induced augmentation of ADLC activity.° However, in contrast with those studies, several other studies have observed no augmentation of ADLC activity.10) It is considered that this discrepancy is possibly caused by a difference of target cells used, i.e. tumor cells were used in the studies demonstrating IFN-induced augmentation of ADLC activity, whereas erythrocytes were mostly used in the studies showing negative results. For example, Rumpold et al. reported that natural human IFN-alpha and -beta did not augment ADLC activity against autologous human RBC coated with antibody.10a) Platsoucas et al. also found no augmentation of the ADCC activity of human peripheral blood non-T lymphocytes by natural human IFN-alpha.10b) Platsoucas further demonstrated that recombinant human IFN-gamma (Cys-Tyr-Cys-Gln form) or -alpha did not augment ADLC activity against IgG-coated CRBC in two-thirds of the donors examined.10c) Taking into consideration their results and ours, it is postulated that IFNs cannot augment ADLC activity against anti-CRBC IgG-coated CRBC. The reason why IFNs can augment ADLC activity against tumor cells but not that against CRBCs is still unclear , but the possibility that CRBCs may be resistant to the enhanced lytic ability of lymphocytes induced by IFNs or that IFNs may not augment the recruitment of lymphocytes binding to anti-CRBC IgG-coated CRBCs cannot be excluded.
It is well known that MHC class II antigens are involved in the presentation of antigens to helper T cells by antigen-presenting cells including macrophages and monocytes.11) The present study demonstrated that IFN-gamma (Met-Gin form) enhanced the expression of Ialike antigen on monocytes, but the two natural IFNs did not. Several investigators reported similar results for recombinant human IFN-gamma (Cys-Tyr-Cys-Gln form).12) Further, Zlotnik et al. reported that recombinant human IFN-gamma (Cys-Tyr-Cys-Gln form) induced the antigen-presenting ability of human macrophage line P388D1 to T cell hybridoma, whereas natural human IFN-alpha and -beta did not.13) Therefore, it is expected that IFN-gamma (Met-Gin form) may enhance the antigen-presenting ability of human monocytes whereas natural IFNs may not.
The lack of enhancing effect of recombinant human IFN-gamma on the expression of Ialike antigens in human lymphocytes demonstrated in this study ( Fig. 5 and Table IV) is consistent with the data reported by Rosa et al.14) However, Lisowska-Grospierre et al . observed enhancement of the expression of HLA-DR antigens on normal human peripheral lymphocytes by recombinant glycosylated human IFN-gamma derived from transformed Chinese hamster ovary cells.15 Although it is still unclear whether the discrepancy was caused by glycosylation of IFN-gamma or not, it seems that human IFN-gamma may enhance the expression of MHC class II antigens on lymphocytes less effectively than that on macrophages and monocytes in humans.
We 
